



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Production Editor**  
Michaela Joseph  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](http://support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products/services/rights-and-licensing/](http://bmj.com/company/products/services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

*The International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

**Statement**

- 561** COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers  
*P T Ramirez, L Chiva, A G Z Eriksson, M Frumovitz, A Fagotti, A Gonzalez Martin, A Jhingran, R Pareja*

**Lead article**

- 564** Comparison of laparoscopic and open radical hysterectomy in cervical cancer patients with tumor size  $\leq 2$  cm  
*X Chen, N Zhao, P Ye, J Chen, X Nan, H Zhao, K Zhou, Y Zhang, J Xue, H Zhou, H Shang, H Zhu, V d M Leanne, X Yan*

**Editorial**

- 572** Safety of minimally invasive radical hysterectomy in cervical tumors  $< 2$  cm  
*R Pareja*

**Surgery**

- 575** Risk of cardiovascular disease after preventive salpingo-oophorectomy  
*N Johansen, S Tonstad, A H Liavaag, R M Selmer, T G Tanbo, T M Michelsen*

**Vulvar Cancer**

- 583** Impact of partnership status on clinical outcomes of patients with vulvar squamous cell carcinoma and performance of sentinel lymph node biopsy  
*A Alhatem, W C Lambert, K Karanfilian, S Behbahani, D Heller*
- 590** Effectiveness of CO<sub>2</sub> laser on urogenital syndrome in women with a previous gynecological neoplasia: a multicentric study  
*R Angioli, S Stefano, M Filippini, A Pieralli, R Montera, F Plotti, A Gatti, M Bartolone, D Luvero*

**Cervical Cancer**

- 596** Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study  
*D Chase, H Q Huang, B J Monk, L M Ramondetta, R T Penson, K Gil, L M Landrum, M Leitao, A Oaknin, W K Huh, H L Pulaski, K Robison, S R Guntupalli, D Richardson, R Salani, M W Sill, L B Wenzel, K S Tewari*

- 602** Consolidation chemotherapy in early-stage cervical cancer patients with lymph node metastasis after radical hysterectomy  
*M L Zhong, Y N Wang, M R Liang, H Liu, S Y Zeng*

- 607** Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy  
*R Lazzari, G Riva, M Augugliaro, A Vavassori, S Diciunzo, F Cattani, S Comi, N Colombo, B A Jereczek-Fossa*

- 613** Effects of HIV status on non-metastatic cervical cancer progression among patients in Lusaka, Zambia  
*M J Trejo, K Lishimpi, M Kalima, C K Mwaba, L Banda, A Chuba, E Chama, S C Msadabve, M L Bell, R B Harris, E Jacobs, A Soliman*

**Uterine Cancer**

- 619** Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix  
*D Nasioudis, M K Frey, E Chapman-Davis, T A Caputo, K Holcomb*
- 626** Comparison of lymphoscintigraphy and single photon emission computed tomography with computed tomography (SPECT/CT) for sentinel lymph node detection in endometrial cancer  
*S Togami, T Kawamura, S Yanazume, M Kamio, H Kobayashi*
- 631** Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged  $\leq 40$  years  
*J Son, C Carr, M Yao, M Radeva, A Priyadarshini, J Marquard, C M Michener, M AlHilli*
- 640** Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments  
*G Beinse, B Rance, P-A Just, B Izac, F Letourneur, N E B Saidu, S Chouzenoux, C Nicco, F Goldwasser, F Bateau, C Durdur, C Chapron, E Pasmant, K Leroy, J Alexandre, B Borghese*

## Ovarian Cancer

- 648** Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer  
*M Z Muallem, J Sehouli, A Miranda, R Richter, J Muallem*
- 654** Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis  
*E Rinninella, A Fagotti, M Cintoni, P Raoul, G Scaletta, G Scambia, A Gasbarrini, M C Mele*
- 664** Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery  
*D Wang, S Zhu, C Jia, D Cao, M Wu, K Shen, J Yang, Y Xiang*

## Reviews

- 670** IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers  
*N R Abu-Rustum, R Angioli, A E Bailey, V Broach, A Buda, M R Coriddi, J H Dayan, M Frumovitz, Y M Kim, R Kimmig, M M Leitao Jr., Z Muallem, M McKittrick, B Mehrara, R Montero, L A Moukarzel, R Naik, S Pedra Nobre, M Plante, F Plotti, O Zivanovic*
- 684** Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review  
*R Arend, S N Westin, R L Coleman*
- 695** British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)  
*C Newton, A Nordin, P Rolland, T Ind, P Larsen-Disney, P Martin-Hirsch, K Beaver, H Bolton, R Peavor, A Fernandes, F Kew, P Sengupta, T Miles, L Buckley, H Manderville, K Gajjar, J Morrison, J Ledermann, J Frost, A Lawrence, S Sundar, C Fotopoulou*

## Clinical trial

- 701** Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer  
*J Mayadev, D Zamarin, W Deng, H Lankes, R O'Ceirbhail, C A Aghajanian, R Schilder*

## Case study

- 705** Locally-advanced vaginal cancer with complete utero-vaginal prolapse  
*A Buda, E Yaprak, R Millani, M Frigerio, R Perego, M Jaconi, S Meregalli*

## Corners of the world

- 709** Passion for saving lives: Turkey between 2012 and 2017  
*M Gultekin, S H Turan, G Boztas, C Öztürk, E Hacikamiloğlu*

## Video articles

- 711** Extraperitoneal en bloc intestinal resection as palliative surgery for treatment refractory bowel obstruction in ovarian cancer relapse  
*C Fotopoulou, D Haidopoulos*
- 712** Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye  
*L C Turco, V Vargiu, C Nero, A Fagotti, G Scambia, F Cosentino*
- 714** Multidisciplinary approach in the pelvic relapse of a previously irradiated cervical tumor  
*D Vázquez-Vicente, T Castellanos, A Cabello, E Chacon, J A Minguéz, L Chiva*

## Miscellaneous

- 715** Correction: *African American women with advanced-stage ovarian cancer have worse outcomes regardless of treatment type*